Adiponectin, its cardioprotective effects and genetic
variability in relation to restenosis after percutaneous
coronary intervention (PCI)

C 2012

Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI)

BIENERTOVÁ VAŠKŮ, Julie, Petr BIENERT a Anna VAŠKŮ

Základní údaje

Originální název

Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI)

Autoři

BIENERTOVÁ VAŠKŮ, Julie (203 Česká republika, garant, domácí), Petr BIENERT (203 Česká republika, domácí) a Anna VAŠKŮ (203 Česká republika, domácí)

Vydání

New York, Adiponectin: Production, Regulation and Roles in Disease, od s. 23-38, 16 s. Endocrinology Research and Clinical Developments, 2012

Nakladatel

Nova Science Publishers

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Forma vydání

tištěná verze "print"

Kód RIV

RIV/00216224:14110/12:00060425

Organizační jednotka

Lékařská fakulta

ISBN

978-1-61942-165-3

Klíčová slova anglicky

adiponectin; percutaneous coronary intervention; restenosis; polymorphism

Změněno: 10. 4. 2013 16:01, Ing. Mgr. Věra Pospíšilíková

Anotace

ORIG CZ

V originále

Restenosis after percutaneous coronary intervention (PCI) represents a major limitation to this procedure and despite large efforts it is still difficult to stratify patients after PCI according to restenosis risk. A wide range of proteins have been investigated in order to establish new diagnostic/prognostic markers of restenosis after PCI, without major effects. Adiponectin, a protein secreted exclusively by the adipose tissue, has recently emerged as an anti-inflammatory, anti-atherogenic, insulin-sensitizing factor providing possible link between white adipose tissue and cardiovascular disease. This crucial role in cardioprotection is mediated via a variety of mechanisms, including inhibition of foam cell formation, expression of antithrombogenic properties and inhibition of smooth muscle cells proliferation, all vital processes in restenosis development. Considering its cardioprotective effects, the role of adiponectin in prediction of adverse cardiovascular events has been studied extensively. However, little attention is paid to adiponectin role in restenosis development after PCI, even though pathophysiology of restenosis covers directly the mechanisms regulated or substantially influenced by adiponectin. The current review describes pathophysiological effects of adiponectin in cardiovascular system, mainly those closely associated with restenosis development and attention is being paid also to the role of genetic variability.

Česky

Adiponektin a jeho kardioprotektivní účinky.

Citovat

BIENERTOVÁ VAŠKŮ, Julie, Petr BIENERT a Anna VAŠKŮ. Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI). In Adiponectin: Production, Regulation and Roles in Disease. New York: Nova Science Publishers, 2012, s. 23-38. Endocrinology Research and Clinical Developments. ISBN 978-1-61942-165-3.

@inbook{987370,
   author = {Bienertová Vašků, Julie and Bienert, Petr and Vašků, Anna},
   address = {New York},
   booktitle = {Adiponectin: Production, Regulation and Roles in Disease},
   keywords = {adiponectin; percutaneous coronary intervention; restenosis; polymorphism},
   howpublished = {tištěná verze "print"},
   language = {eng},
   location = {New York},
   isbn = {978-1-61942-165-3},
   pages = {23-38},
   publisher = {Nova Science Publishers},
   title = {Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI)},
   year = {2012}
}

TY  - CHAP
ID  - 987370
AU  - Bienertová Vašků, Julie - Bienert, Petr - Vašků, Anna
PY  - 2012
TI  - Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI)
VL  - Endocrinology Research and Clinical Developments
PB  - Nova Science Publishers
CY  - New York
SN  - 9781619421653
KW  - adiponectin
KW  - percutaneous coronary intervention
KW  - restenosis
KW  - polymorphism
N2  - Restenosis after percutaneous coronary intervention (PCI) represents a major limitation to this procedure and despite large efforts it is still difficult to stratify patients after PCI according to restenosis risk. A wide range of proteins have been investigated in order to establish new diagnostic/prognostic markers of restenosis after PCI, without major effects. Adiponectin, a protein secreted exclusively by the adipose tissue, has recently emerged as an anti-inflammatory, anti-atherogenic, insulin-sensitizing factor providing possible link between white adipose tissue and cardiovascular disease. This crucial role in cardioprotection is mediated via a variety of mechanisms, including inhibition of foam cell formation, expression of antithrombogenic properties and inhibition of smooth muscle cells proliferation, all vital processes in restenosis development. Considering its cardioprotective effects, the role of adiponectin in prediction of adverse cardiovascular events has been studied extensively. However, little attention is paid to adiponectin role in restenosis development after PCI, even though pathophysiology of restenosis covers directly the mechanisms regulated or substantially influenced by adiponectin. The current review describes pathophysiological effects of adiponectin in cardiovascular system, mainly those closely associated with restenosis development and attention is being paid also to the role of genetic variability.
ER  -

BIENERTOVÁ VAŠKŮ, Julie, Petr BIENERT a Anna VAŠKŮ. Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI). In \textit{Adiponectin: Production, Regulation and Roles in Disease}. New York: Nova Science Publishers, 2012, s.~23-38. Endocrinology Research and Clinical Developments. ISBN~978-1-61942-165-3.

Podrobný výpis o publikaci